A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma

Cancer Research

Volumn 66, Issue 20, 2006, Pages 9852-9861

  Jenkins, Robert B ^a,d   Blair, Hilary ^a   Ballman, Karla V ^a   Giannini, Caterina ^a   Arusell, Robert M ^b   Law, Mark ^a   Flynn, Heather ^a   Passe, Sandra ^a   Felten, Sara ^a   Brown, Paul D ^a   Shaw, Edward G ^c   Buckner, Jan C ^a  

^a MAYO CLINIC   (United States)

^b Merit Care Community Clinical Oncology Program   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOMUSTINE; PROCARBAZINE; VINCRISTINE;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER RADIOTHERAPY; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GLIOMA; HUMAN; INTERPHASE; MAJOR CLINICAL STUDY; MALE; METAPHASE; OLIGODENDROGLIA; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; STEM CELL; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; CELL CYCLE PROTEINS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 12; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; FEMALE; HUMANS; INTERPHASE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OLIGODENDROGLIOMA; PROGNOSIS; TRANSLOCATION, GENETIC;

EID: 33750563258     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1796     Document Type: Article

References (41)

1. Ransom DT, Ritland SR, Kimmel DW, et al. Cytogenetic and loss of heterozygosity studies in ependymomas, pilocytic astrocytomas, and oligodendrogliomas. Genes Chromosomes Cancer 1992;5:348-56.
2. Bello MJ, Vaquero J, de Campos JM, et al. Molecular analysis of chromosome I abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors. Int J Cancer 1994;57:172-5.
3. van den Bent MJ, Looijenga LH, Langenberg K, et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 2003;97: 1276-84.
4. Felsberg J, Erkwoh A, Sabel MC, et al. Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol 2004;14:121-30.
5. Okamoto Y, Di Patre PL, Burkhard C, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol (Berl) 2004;108: 49-56.
6. Smith JS, Tachibana I, Lee HK, et al. Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. Genes Chromosomes Cancer 2000;29:16-25.
7. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-9.
8. Ino Y, Zlatescu MC, Sasaki H, et al. Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg 2000;92:983-90.
9. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000;18:636-45.
10. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006;24:2707-14.
11. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006;24:2715-22.
12. Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 2002;20:2267-76.
13. Buckner JC, Gesme D, Jr., O'Fallon JR, et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 2003;21:251-5.
14. Korhonen L, Brannvall K, Skoglosa Y, Lindholm D. Tumor suppressor gene BRCA-1 is expressed by embryonic and adult neural stem cells and involved in cell proliferation. J Neurosci Res 2003;71:769-76.
15. Shaffer LG, Tommerup N, editors. ISCN (2005): guidelines for cancer cytogenetics. A supplement to an International System for Human Cytogenetic Nomeclature. New York: S. Karger; 2005. p. 80-1.
16. Martin-Subero JI, Harder L, Gesk S, et al. Interphase FISH assays for the detection of translocations with breakpoints in immunoglobulin light chain loci. Int J Cancer 2002;98:470-4.
17. UCSC Genome Browser on Human May 2004 Assembly Chromosome 19p12-q12. Available from: http://genome.ucsc.edu/cgi-bin/hgTracks, http://genome.ucsc.edu/ cgi-bin/hgc?hgsid=67301676&o= 26700000&t=28500000&g=cytoBand&i= p11&c= chr19&l=24107630&r=32298603&db=hg17&pix=620.
18. Bigner SH, Mark J, Bigner DD. Cytogenetics of human brain tumors. Cancer Genet Cytogenet 1990;47:141-54.
19. Magnani I, Guerneri S, Pollo B, et al. Increasing complexity of the karyotype in 50 human gliomas. Progressive evolution and de nova occurrence of cytogenetic alterations. Cancer Genet Cytogenet 1994; 75:77-89.
20. Jeuken JW, Sprenger SH, Wesseling P, et al. Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization. J Neuropathol Exp Neurol 1999;58:60612.
21. Kros JM, van Run PR, Alers JC, et al. Genetic aberrations in oligodendroglial tumours: an analysis using comparative genomic hybridization (CGH). J Pathol 1999;188:2828.
22. Bigner SH, Matthews MR, Rasheed BK, et al. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 1999;155:375-86.
23. Smith JS, Alderete B, Minn Y, et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 1999;18:4144-52.
24. Magnani I, Chiariello E, Conti AM, Finocchiaro G. A recurrent 19q11-12 breakpoint suggested by cytogenetic and fluorescence in situ hybridization analysis of three glioblastoma cell lines. Cancer Genet Cytogenet 1999; 110:82-6.
25. Baldini A, Smith DI, Rocchi M, Miller OJ, Miller DA. A human alphoid DNA clone from the EcoRI dimeric family: genomic and internal organization and chromosomal assignment. Genomics 1989;5:822-8.
26. Horiike S, Taniwaki M, Misawa S, et al. The unbalanced 1:7 translocation in de novo myelodysplastic syndrome and its clinical implication. Cancer 1990;65: 1350-4.
27. Hermsen M, Snijders A, Guervos MA, et al. Centromeric chromosomal translocations show tissue-specific differences between squamous cell carcinomas and adenocarcinomas. Oncogene 2005;24:1571-9.
28. Xu GL, Bestor TH, Bourc'his D, et al. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature 1999;402:187-91.
29. Gisselsson D, Shao C, Tuck-Muller CM, et al. Interphase chromosomal abnormalities and mitotic missegregation of hypomethylated sequences in ICF syndrome cells. Chromosoma 2005;114:118-26. Epub 2005 Apr 27.
30. Croft JA, Bridger JM, Boyle S, Perry P, Teague P, Bickmore WA. Differences in the localization and morphology of chromosomes in the human nucleus. J Cell Biol 1999;145:1119-31.
31. Osborne CS, Chakalova L, Brown KE, et al. Active genes dynamically colocalize to shared sites of ongoing transcription. Nat Genet 2004;36:1065-71.
32. Toyota M, Issa JP. Epigenetic changes in solid and hematopoietic tumors. Semin Oncol 2005;32:521-30.
33. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002;21:5400-13.
34. Wong N, Lam WC, Lai PB, Pang E, Lau WY, Johnson PJ. Hypomethylation of chromosome 1 heterochromatin DNA correlates with q-arm copy gain in human hepatocellular carcinoma. Am J Pathol 2001;159:465-71.
35. Saito Y, Kanai Y, Sakamoto M, Saito H, Ishii H, Hirohashi S. Overexpression of a splice variant of DNA methyltransferase 3b, DNMT3b4, associated with DNA hypomethylation on pericentromeric satellite regions during human hepatocarcinogenesis. Proc Natl Acad Sci U S A 2002;99:10060-5. Epub 2002 Jul 10.
36. Nakagawa T, Kanai Y, Ushijima S, Kitamura T, Kakizoe T, Hirohashi S. DNA hypomethylation on pericentromeric satellite regions significantly correlates with loss of heterozygosity on chromosome 9 in urothelial carcinomas. J Urol 2005;173:243-6.
37. Wolter M, Reifenberger J, Blaschke B, et al. Oligodendroglial tumors frequently demonstrate hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) tumor suppressor genes. J Neuropathol Exp Neurol 2001;60:1170-80.
38. Law ME, Templeton KL, Kitange G, et al. Molecular cytogenetic analysis of chromosomes 1 and 19 in glioma cell lines. Cancer Genet Cytogenet 2005;160:1-14.
39. Sasaki H, Zlatescu MC, Betensky RA, et al. Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma." J Neuropathol Exp Neurol 2002;61:58-63.
40. Hoang-Xuan K, Capelle L, Kujas S, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004; 22:3133-8.
41. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8.